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Abstract. Bi, a high atom number element, has a high photoelectric absorption coefficient, 
and Se element has anticancer activity. Hence, their compound chalcogenide (Bi2Se3) 
deserves a thorough investigation for biomedical applications. This study reveals that Bi2Se3 
nanoplates (54 nm wide) protected with poly(vinylpyrollidone) (PVP) are biocompatible and 
have low toxicity even at a high dose of 20 mg/kg in mice. This conclusion was made through 
the studies on the biodistribution and 90-day long term in vivo clearance of the nanoplates. 
Liver and spleen were dominant organs for the nanoplates accumulation which was mainly 
due to RES absorption, but 93 % the nanoplates were cleared after 90 days treatment. 
Concentrations of Bi and Se in tumor tissue continuously increased until 72 h after 
intraperitoneal injection into mice. Such selective accumulation of Bi was utilized to enhance 
the contrast of X-ray CT images. The Bi elements concentrated in a tumor led to damage on 
the tumor cells when exposed to gamma radiation. Growth of the tumor significantly delayed 
and stopped after 16 days after the tumor was treated with the Bi2Se3 nanoplates and radiation. 
This work clearly shows that the Bi2Se3 nanoplates may be used for cancer radiation therapy 
and CT imaging. They deserve further studies for biological and medical applications. 
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1. Introduction 
Bismuth selenide (Bi2Se3) has attracted wide interest in condensed matter physics due to 
the high thermoelectric figure of merit and the unique surface electronic states as a 
topological insulator.[1-7] Its biomedical applications, however, have rarely been explored. Se 
is a natural anticancer element which can inhibit reactive oxygen species.[8] Bi is a high atom 
number material (Z=83) and it has a high photoelectric absorption coefficient (5.3 cm2/g at 
100 keV) which is higher than those of I, Au, and Pt. The large X-rays absorption is 
advantageous for the use as cancer radio sensitizer and X-ray contrast agent.[9-13] Thus, Bi2Se3 
nanoparticles deserve a thorough biomedical investigation for the high radiation enhancement 
effect and the cancer radiation therapy.  
Interaction between nanostructured materials and biological system is closely related to 
surface chemistry.[14-23] Nanoparticles without a protected organic layer are agglomerated 
immediately in blood due to the strong interaction with serum proteins.[13,24] The size of the 
particle also strongly influences the mechanism of clearance in body.[23,25-30] It is well 
documented that nanoparticles during long time circulation in blood can be continuously 
accumulated in tumor cells through the enhanced permeability and retention (EPR) of the 
cancerous cells.[30-35] Coating with poly(vinylpyrrolidone) (PVP) on nanoparticles have been 
reported to prolong the circulation, and such nanoparticles have been successfully utilized in 
X-ray imaging,[36] MRI imaging,[37] and photothermal cancer therapy.[38]  
Investigation of the toxicity and clearance of new materials is important for possible 
medical applications.[39-41] Clearance routes through liver and kidney are crucial in 
metabolism of materials. Nanoparticles smaller than 5.5 nm can be cleared rapidly by renal 
clearance,[42] while nanoparticles in the range of 10-50 nm can be absorbed by the first-pass 
extraction from the reticuloendothelial system (RES).[43,44] Nanoparticles larger than 50 nm 
can be cleared partially by the liver metabolism.[45-48] For example, a recent toxicological 
investigation in monkeys showed that 52 nm CdSe quantum dots encapsulated with 
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phospholipids micelle could be partially cleared after 90 days treatment.[49] Thus, searching 
metabolizable nanomaterials with efficient biological activity and evaluating their biological 
response are important for medical application of the materials. 
In this work, the PVP-coated Bi2Se3 nanoplates (NPs, 53.8 nm in width and less than 6 nm 
in thickness) were employed to investigate their integration in tumor cells and the possibility 
of the use in the cancer radiation therapy and the X-ray computed tomography (CT) imaging. 
The Bi2Se3 NPs intraperitoneally injected in mice exhibited continuous accumulation in the 
tumor cells. The Bi elements in tumor significantly enhanced the tumor radiation. Moreover, 
90 days long-term toxicological response showed that 93 % Bi2Se3 NPs can be metabolized, 
and no any toxicity were found. This work suggests a new way of cancer therapy and CT 
imaging with Bi2Se3 NPs. 
 
2. Results and discussions 
2.1 Analysis of the PVP-stabilized Bi2Se3 nanoplates  
Previously, we have reported the formation of ultra-thin single crystal Bi2Se3 nanodiscs 
and nanosheets in the presence of PVP.[50] We modified the synthetic path to decrease the size 
of the NPs. Stoichiometric ratio of sodium selenite (Na2SeO3) and bismuth nitrate 
pentahydrate (Bi(NO3)3·5H2O) were dissolved in ethylene glycol with mild stirring. At 180 °C, 
reduction was triggered by rapid injection of an ethylene glycol solution of hydrazine hydrate. 
Details are found in the experimental section. The as-synthesized NPs were two dimensional 
plates (Figure 1a,b). Bi2Se3 preferentially forms a two dimensional layered structure. 
Consecutive five atomic layers stack along the c-axis (Se1–Bi–Se2–Bi–Se1) which is a 
quintuple layer (QL~1 nm).[51] PVP can bind to basal plane composed of negatively charged 
elemental Se. Average lateral size of the NPs was ~ 53.8 nm from TEM images (Figure S1a) 
which is consistent with the hydrodynamic diameter (59.8 nm) obtained by dynamic light 
scattering (Figure S1b). High-resolution TEM images show the crystal structure of the NPs 
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(Figure 1c,d). The hexagonal lattice fringes with a lattice spacing of 0.207 nm (Figure 1c) 
represent the lattice spacing of the (110) plane. The cross-section image (Figure 1d) shows a 
lattice spacing of 0.478 nm which corresponds to the (006) plane. Powder X-ray diffraction 
(XRD) confirms that the Bi2Se3 NPs have the rhombohedral crystal structure with lattice 
constants of a=0.4139 nm and c=2.8636 nm (Figure 1e). The NPs in this study show a good 
agreement with the peaks of bulk Bi2Se3 with the same crystal structure indicated by the blue 
vertical lines.[52] The NPs were stabilized by PVP surfactant so that they were dispersed well 
in water. The zeta potential of the NPs in pure water was -16.69 mV, which is in a regime of 
stable dispersion. We tested the time-dependent stability of the NPs, and found that 
hydrodynamic diameter was stable and no significant aggregation was occurred in the 
phosphate-buffered saline (PBS) after 1 month (Figure S1b). Inspired by these results, we 
tested the biological response of the Bi2Se3 NPs in mice. 
2.2 Biodistribution and clearance of the Bi2Se3 nanoplates 
Knowledge on the biodistribution and clearance of a material is critical for the medical 
treatment and long-term toxicity. The NPs solution (2 mg/mL, 0.2 mL) was injected 
intraperitoneally into C57 male mice (64 mice, 8 per group). Final dose in the mice was 20 
mg/kg. The mice were scarified in 1, 7, 30, and 90 days, and main organs from 3 mice per 
group were tested by inductively coupled plasma mass spectrometry (ICP-MS). And then, the 
biodistributions of Bi from the PVP-protected Bi2Se3 NPs were obtained (Figure 2a). It is 
clear that liver, spleen, and kidney are the main target organs, and the bladder and testis are 
the next. Heart, lung, and brain showed relatively low Bi concentrations. Bi concentration was 
as high as 163.2 μg/g in liver, 101.9 μg/g in spleen, and 46.8 μg/g in kidney after 1 day. After 
90 days, Bi concentration decreased to 9.26 μg/g in liver, 6.93 μg/g in spleen, and 0.78 μg/g in 
kidney. Biodistributions of Se in all organs are presented in Figure 2b. After 1 day treatment, 
Se also showed the highest uptake in liver, spleen, and kidney, with concentrations of 12.8, 
10.9, and 4.25 μg/g, respectively. After 90 days, Se concentration decreased to 1.83 μg/g in 
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liver, 0.23 μg/g in spleen, and 0.42 μg/g in kidney, respectively. The PVP layer prolonged the 
blood circulation time of the NPs.[53,54] It is not surprising that NPs larger than 10 nm can 
enter excretion system through the RES process. Phagocytosis by the Kupffer cells and spleen 
macrophages are significantly dependent on particle size. The larger particles can induce 
greater uptake by RES.44,55] Further, it can be noticed that Bi concentration in all organs 
decreased with the increase of treatment days, which indicates the time-dependent clearance 
effects (Figure 2a). Se was detected mainly in liver, spleen, kidney, and bladder. Se 
concentration decreased in the organs until 30 days, but it increased in kidney, testis, and 
bladder after 90 days.  
To investigate the clearance in detail, the time-dependent residual amount in mice from 
the injected Bi2Se3 NPs were investigated (Figure 2c,d). Residual amount of Bi and Se in 
mice were calculated by summing the Bi and Se amount in all organs from Figure 2a and 2b, 
respectively. The ICP-MS measurements showed that the initial total amount of Bi and Se 
was 190.76 and 124.68 μg, respectively. The residual ratios of Bi and Se were calculated by 
the residual amount / initial total amount. It was found that the residual amount of Bi in body 
after 1 day was 164.95 μg, and it was decreased to 11.66 μg after 90 days, which corresponds 
to 86.5 % of the initial amount after 1 day and 6.1 % after 90 days. Similar behavior was 
observed for Se. The residual amount was 13.43 μg after 1 day, and it decreased to 1.58 μg 
after 90 days, which indicated 10.8 % after 1 day and 1.3 % after 90 days. It is proposed that 
small NPs below 5.5 nm can be cleared by kidney, while large NPs above 50 nm may be 
partially cleared by liver as the time increased.[42] Thus, clearance by liver is a significant 
contribution to the decrease of the Bi2Se3 NPs in mice. Meanwhile, it is worth noting that high 
concentration of Bi and Se can also be found in kidney, indicating that kidney may participate 
in the partial metabolism of the NPs. It is similar to the previous work in which 50 nm Au 
particles showed unexpected high distribution in kidney.[44] Indeed, it was demonstrated that 
10-30 nm graphene nanosheets could be cleared by both liver and kidney.[56,57] However, it is 
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not clear whether metabolism of other organs is related to the breakdown of NPs in vivo. The 
NPs indeed can be degraded and excreted with long time blood circulation and physiological 
environment.[47] 
It is notable that from the results in Figure 2, the Bi concentration was about 10 times 
higher than that of Se concentration. The as-synthesized Bi2Se3 NPs were stoichiometric, with 
a Bi/Se ratio of ~1.53 that was obtained from ICP-MS and energy dispersive spectrometer 
(EDS). The Bi2Se3 NPs were found to be oxidized easily in air environment. We found that 
the dry Bi2Se3 NPs powder was oxidized slowly to form Bi2O3-x, and pure Se was phase 
separated to form large aggregates. The same oxidation process was observed in the PBS 
buffer solution (pH=7.4). The Bi2Se3 powder suspended in the PBS buffer solution showed a 
slow oxidation process when they were exposed to air. We could not detect the trace of 
oxidation within a few days. However, severe oxidation was observed in one month. As seen 
in Figure 3a, the red amorphous Se was dissolved in the buffer solution and then precipitated 
on the glassware (indicated with an arrow). TEM image (Figure 3b) presents the shape 
deformation of the NPs into irregular amorphous-like particles which is due to the existence 
of amorphous Se (indicated with an arrow). The XRD peaks (Figure 3c) corresponds to a 
mixture of Bi2O2.33 and residual Bi2Se3, which confirms the replacement of Se by oxygen. 
Therefore, the as-synthesized NPs were preserved in Ar environment to prevent possible 
oxidation. The NPs before injection was identical in chemical composition and crystal 
structure to the as-synthesized ones.  
The surprising mismatch of the atomic ratio before and after injection indicates fast 
oxidation of the NPs in mouse body. When the aqueous solution of the NPs was mixed with 
the blood plasma in vitro, the weight ratio of Bi/Se rapidly increased to 9.8 after 0.5 h, and 
further increased to 11.7 after 24 h (Figure 4a). These results confirm the fast oxidation of the 
NPs, which dissolves Se in mice blood. We further confirmed it by in vivo experiment. After 
in vivo injection, the Bi concentration sharply increased after 1 h and then decreased rapidly. 
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In contrast, the Se concentration reached a relatively stable level. The Bi/Se atomic ratio 
reached 5:1 after 1 h, but it decreased rapidly to 0.2 after 72 h (Figure 4b). Figure 4c 
schematically depicts the oxidation process in blood. The oxidized NPs or the pristine NPs 
were absorbed by RES, but Se atoms dissolved in blood remaining in the blood plasma. 
Probably existing in the complex forms with the biomolecules in the blood, Se could circulate 
for a long time in blood. Further, the Se dissolved in blood could be metabolized by renal 
clearance and thus accumulates in bladder.[42,58,59] Similar phenomenon has been reported in 
previous work where the PEG-coated gold NPs presented accumulation in organ after 90 days 
treatment.[45]  
2.3 Toxicity of the Bi2Se3 nanoplates 
We next investigated the in vivo toxicity of Bi2Se3 NPs at the dose of 20 mg/kg by 
evaluating body weight, immune response, hematology, and biochemistry at the time points 
of 1, 7, 30, and 90 days. During the 90 days period, the treatment with Bi2Se3 NPs did not 
cause obvious adverse effects on growth, and no meaningful statistical differences were 
observed in body weight and thymus index between the Bi2Se3 NPs-treated mice and control 
mice (Figure S2a and S2b). Spleen index in the NPs-treated mice increased steadily by 30 
days, but it decreased after 90 days (Figure S2c). We selected standard hematology markers 
for analysis, including white blood cell (WBC), red blood cell (RBC), hematocrit (HCT), 
mean corpuscular volume (MCV), hemoglobin (HGB), platelet (PLT), mean corpuscular 
hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC). Hematology 
results for the Bi2Se3 NPs are presented in Figure 5a. For the NPs-treated mice, two typical 
indicators (WBC, RBC) have not shown meaningful differences from those of the untreated 
mice. PLT increased after 30 days treatment, but recovered after 90 days treatment. Other 
parameters (MCV, MCH, MCHC, HGB, HCT) had no significant difference. These results 
present limited biological damage to the mice. When the NPs were injected into the mice, 
they would interact with all serum protein, such as albumin, fibrinogen, γ-globulin, histone, 
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and insulin. The blood chemistry of mice has not been affected directly. The PVP protected 
layer plays as a blood compatible surface coating layer, which is consistent with the previous 
works.[36,60] Compared with the Au-based nanomaterials at a similar dose range (10~20 
mg/kg), the PVP-protected Bi2Se3 NPs caused less toxic responses. The PEG-coated Au NPs 
resulted in acute increase of RBC and WBC by intraperitoneal and oral injections because 
RBC and WBC are sensitive to infection and inflammation caused by the Au NPs.[43,45,59,61-63] 
These results show that the PVP-protected Bi2Se3 NPs do not cause significant infection and 
inflammation for mice.  
Furthermore, we performed the standard biochemistry examination with the mice treated 
by the Bi2Se3 NPs at the different time points of 1, 7, 30, and 90 days (Figure 5b). The 
biochemical parameters including (a) alanine transaminase (ALT), (b) aspartate transaminase 
(AST), (c) total protein (TP), (d) albumin (ALB), (e) blood urea nitrogen (BUN), (f) 
creatinine (CREA), (g) globulin (GLOB), and (h) total bilirubin (TBIL) were investigated. We 
emphasize ALT, AST, and CREA because they are closely related to the functions of liver 
and kidney of mice. Meaningful changes were not observed in all parameters after 1 day. The 
NPs presented appreciable liver accumulation after 1 day, but did not cause acute injury at 
this time point. After 7 days treatment, ALT significantly increased in the NPs treated mice, 
while AST and CREA did not have noticeable difference in the treated mice. After 90 days, 
ALT has changed back to a normal level which indicates that the Bi2Se3 NPs caused slight 
damage for liver after 7 days, but the damage recovered after 30 and 90 days. It is consistent 
with the biodistribution and clearance of the NPs. It is widely reported that the liver 
accumulation of Au and metal oxide nanomaterials can induce continuous increase of ALT 
and AST, and thus significant damage in liver. Even at the dose level of 5 mg/kg through 
intravenous injection, Au nanoparticles and nanoclusters stabilized by PEG and BSA caused 
acute damage even after 90 days.[59,61] Similarly, the PEG- and Oleic acid-coated Fe3O4 
nanocrystals with the size of 5-30 nm led to steady increase of ALT, AST, and BUN at the 
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dose of 5-7.5 mg/kg.[64] However, the Bi2Se3 NPs showed very low liver toxicity even at 20 
mg/kg dose.  
Finally, we checked the pathological changes of organs by using immunohistochemistry 
at different time points. We collected liver, spleen, and kidney, and sliced them for 
Haematoxylin and Eosin (H&E) staining (Figure 6). No significant organ damages were 
observed in spleen and kidney during the whole treatment period. Slight pathological change 
was shown in liver after 7 days treatment, but it was recovered to the normal state after 90 
days treatment. No noticeable toxic effects were detected in heart, lung, testis, bladder, and 
brain (Figure S3). Another feature of pathology is to qualitatively investigate the clearance of 
the Bi2Se3 NPs.57,64 When the NPs are accumulated in an organ, they may aggregate and 
permit direct observations through optical microscope. A large number of dark spots (less 
than 1 μm) were found in spleen after 1 and 7 days treatment, but they were cleared after 90 
days. Similar results were reported for carbon nanotube, graphene, and Fe3O4 NPs treated 
mice. Black spots were observed in liver, but they eventually disappeared after about 90 days.  
Currently, nanomedicine is searching for materials with low toxicity and highly efficient 
clearance. It is widely accepted that small size nanoparticles can be cleared by kidney. Actual 
situation, however, is far more complex than the expectation. A case in point is about 
clearance of Au nanoparticles. The PEG-protected Au nanoparticles (3 nm) could not be 
cleared, but glutathione (GSH)-protected Au nanoparticles with the same size showed 
efficient renal clearance.[59,65] Carbon materials could be gradually cleared by kidney and liver 
when the size was up to 10~30 nm.[57] Therefore, it is shown that the clearance of 
nanomaterials is not only related to size and surface chemistry, but also related to the shape 
and stability. Exploring clearance of large size materials provides another available route for 
design of metabolizable nanomaterials. Present work clearly shows that the PVP-protected 
Bi2Se3 NPs can be metabolized by liver, hence they have large room for medical applications 
such as contrast agent and cancer therapy. 
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2.4 Cancer radiation therapy of the Bi2Se3 nanoplates 
The cell responses (or biocompatibility) of the PVP-protected Bi2Se3 NPs were evaluated 
using the Hela cells. The Hela cell was treated by the Bi2Se3 NPs with different 
concentrations of 1.56 ~ 200 μg/mL. As shown in Figure 7a, the viabilities of the cells 
changed very little after 24 h and 48 h as the concentration of the NPs was increased, which 
indicates a low cytotoxicity even at a high dosage of 200 μg/mL. The in vitro radiation 
enhancement of the Bi2Se3 NPs was measured by the MTT assay using the Hela cells. As 
shown in Figure 7b, obvious enhancement in radiation with increasing dosage was observed 
for the cell cultures treated with the Bi2Se3 NPs. The radiation enhancement is regarded to be 
caused by increased DNA damage induced by the photoelectric effect and Compton scattering 
of the heavy metal (Bi).[66,67] This hypothesis was confirmed by the single-cell gel 
electrophoresis study. Without radiation, negligible DNA damage was observed for the cell 
treated with the NPs (Figure 7c). In contrast, after receiving 3 Gray (Gy) radiation dose, the 
DNA damage in the NPs-treated culture was much more significant than in the untreated 
culture (Figure 7c). The remarkable DNA damage was also confirmed by the in vitro imaging 
via the fluorescent DNA stain (Figure 7d). Long tails observed in the stain indicate significant 
DNA damage. There was no obvious DNA damage without radiation in both cells 
with/without NPs treatment, while long tails of stain were easily observed in the cells of the 
NPs-treated culture after 3 Gy radiations. It is clear that Bi2Se3 NPs is biocompatible and it 
can enhance DNA radiation damage. Radiation enhancement of the Bi2Se3 NPs is comparable 
with Au nanoparticles.[59]  
Inspired by these results, we next investigated the in vivo biodistribution of the PVP-
protected Bi2Se3 NPs using U14 tumor-bearing male nude mice (24 mice, 3 per group) after 
intraperitoneal injection (2 mg/mL, 0.2 mL) at the dose of 20 mg/kg. We used the inductively 
coupled plasma mass spectrometry (ICP-MS) to measure the concentrations of Bi and Se in 
blood at different time points of 0.5, 1, 2, 6, 12, 24, 48, and 72 h (Figure 8a). The 
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concentrations of both Bi and Se sharply decreased in the first phase, and then gradually 
decreased in the second phase. In the first phase, the blood concentrations decayed to their 
half in 1.9 h for Bi and in 1.5 h for Se. The blood circulation times were lower that of 10-40 
nm PEG-coated Au particles,[43,68,69] but higher than those of quantum dots.[32,68,70,71] Time-
dependent concentrations of Bi and Se in tumor tissues were obtained from the same mice 
(Figure 8b). The Bi concentration in the tumor gradually increased from 0.35 μg/g (1.75 % 
ID/g) in 0.5 h to 1.48 μg/g (7.4 % ID/g) in 72 h, and then approached a plateau value in ~ 24 h. 
The concentration of Se in the tumor tissue increased from 0.25 μg/g in 0.5 h to 0.42 μg/g in 
72 h. It is definite that the uptake in the tumor of the NPs is accumulated in tumor tissue by 
the passive targeting effect, which is consistent with previous works.[72,73] Further, it is found 
that the Bi concentration was close to the reported values of the Au nanoparticles (6.25 % 
ID/g) and the Au nanorods (7 % ID/g) accumulated in tumor tissues in 72 h after injection 
with the same dose.[68,69,71]  
Encouraged by the highly effective accumulation of Bi in tumor cells, in vivo cancer 
radiation therapy was carried out by using U14 tumor-bearing nude mice. The PVP-protected 
Bi2Se3 NPs were intraperitoneally injected into mice (20 mg/kg). After 24 h, the mice were 
locally irradiated under 137Cs gamma radiation of 3600 Ci at the dose of 5 Gy. The volume of 
the tumor was monitored by student T-test (Figure 8c). Without the radiation treatment, the 
tumor volume at the beginning steadily increased to 3.2 times larger after 25 days, regardless 
of the existence of the NPs. With the radiation treatment, the growth of the tumor volume in 
the mice without NPs injection (radiation only) was retarded by 6 days, but the tumor 
eventually grew to 2.4 times after 25 days. The tumor volume of the NPs-treated mice with 
radiation was 1.47 times after 25 days, which is a significant reduction in growth rate. It is 
notable that the tumor volume did not increase after 16 days until 25 days. Similarly, the 
tumor weight of the mice treated with NPs plus radiation exhibited a net increase of 0.1 g 
from the initial weight (0.21 g), which was less than the control mice and the mice with 
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radiation only (Figure 8d). These in vivo results present that the PVP-protected Bi2Se3 NPs 
have a strong radiation enhancement effect and may be used as a radiosensitizer. Cancer 
radiation therapy of heavy metal elements mainly depends on the concentration in tumor and 
the photoelectric absorption. The photoelectric absorption coefficient of Bi is 0.12 cm2/g at 
radiation energy of 600 keV which is higher than that of Au (0.08 cm2/g) at the same radiation 
energy. The effective accumulation in tumor tissue and the unique x-ray absorption induce 
obvious inhabitation of tumor growth after radiation.74  
2.5 X-ray CT imaging of the Bi2Se3 nanoplates. 
We next performed the in vivo X-ray CT imaging of the Bi2Se3 NPs in the mice bearing 
U14 tumor. The Bi2Se3 NPs (100 mg/ml, 0.2 ml) were intraperitoneally injected before 
anaesthesia. Three and two dimensions CT imaging were used to evaluate the tumor uptake 
and clearance (Figure 9). Three dimension imaging reveals the tumor outlines and boundaries 
of the tumor sites (indicated by the red circle) at 24 h after the injection of the Bi2Se3 NPs 
(Figure 9a). The Bi2Se3 NPs were also observed in the bladder (Figure 9 b), which indicates 
that the NPs were partially cleared by kidney. Figure 9c-e show time-dependent two 
dimension CT imaging of the Bi2Se3 NPs. The tumor boundary was not clear at 3 h, but it was 
discriminated gradually as the time increased to 24 h, which is attributed to the passive 
accumulation of the NPs in tumor. Figure 9f-h show the bladder. The bladder was seen clearly 
at 3 h and started to lose its intensity after 24 h,  which indicates the time-dependent renal 
clearance effect. It was reported that small particles (<5.5 nm) can be cleared by 
kidney.[42,58,59] Our work, however, suggest the Bi2Se3 NPs can also be metabolized partially 
by renal clearance. The X-ray CT imaging is related to atom number and relative ratio of 
organ/muscle. Au nanoparticles were reported to be used as X-ray contrast agent at the 
concentration of 100 mg/g.[75,76] In our work, X-ray CT imaging with the Bi2Se3 NPs could 
exhibit the clear boundary between tumor and normal tissue at the similar concentration with 
the Au nanoparticles. 
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3. Conclusion 
This study explored the distribution of the Bi2Se3 nanoplates (NPs) (53.8 in width, 6 nm 
in thickness) in the U14 tumor-bearing male mice. The NPs stabilized with PVP exhibited a 
long blood circulation half-life (>50 h). We investigated the in vivo toxicity, biodistribution, 
and clearance of the PVP-protected Bi2Se3 NPs at the dose of 20 mg/kg. It was found that 
liver and spleen were main target organs. Large amount of Bi were found in liver and spleen 
after 1 day treatment (~163.2 μg/g in liver, ~101.9 μg/g in spleen), but more than 93 % of Bi 
were cleared after 90 days treatment. The concentrations of Bi and Se in the organs 
significantly decreased after 25 days, but the accumulation of Bi in the tumor cells increased 
through the enhanced permeability and retention (EPR) of the cancerous tumors. The Bi 
elements accumulated in the tumor cells were employed as a radiosensitizer to inhibit the 
growth of the cancer cells and enhance the contrast in the computerized tomography (CT) 
imaging. Once treated with the NPs and radiation, the growth of the cancer cells was 
significantly delayed and the cancer cells did not further grow after 16 days. This work 
suggests a new way of radiation cancer therapy employing the Bi2Se3 nanoplates. The effect 
of diverse surface stabilizers on the circulation time and biodistribution of Bi in the tumor 
cells is left for the future study.   
 
4. Experimental section 
Materials and synthesis: 1.0 g of poly(vinylpyrrolidone)(PVP, Mw=55 000, Sigma-Aldrich) 
was dissolved in 50 ml of ethylene glycol (EG,  ≥ 99 %, J. T. Baker), and the solution was 
poured in 250 ml round-bottom flask. A solution of sodium selenite (99 %, Aldrich, 0.242 g 
in 40 ml of EG) and a solution of bismuth nitrate pentahydrate (99.99+ %, Aldrich, 0.452 g in 
15 ml of EG) were added to the PVP solution under magnetic stirring at room temperature. 
The flask was sealed and heated to 180 °C in nitrogen environment. As the reaction 
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temperature increased, transparent reaction mixture became milky white and turned yellow-
white. Hydrazine hydrate solution (2 ml in 20 ml of EG) was rapidly injected to the mixture 
by a syringe. The reaction mixture turned dark immediately, which indicates the formation of 
the PVP-protected Bi2Se3 NPs. The reaction was allowed to proceed for 30 min for a complete 
reaction and cooled down to room temperature. The final products were precipitated by 
centrifuging (12,000 rpm, 10 min) and washed three times with a mixture of acetone (300 
mL) and D.I. water (60 mL).  And, the precipitate was washed with pure DI water twice and 
dried in vacuum. 
Material characterization: Transmission electron microscope (TEM) analysis was 
conducted at 200 kV with JEOL models (JEM-2100F and JEM-2011HC). X-ray diffraction 
(XRD) measurement was performed with a Rigaku D/MAX II x-ray diffractrometer at Cu K 
radiation (λ = 0.1542 nm). The scanning range extended from 10 to 80°with a speed of about 
3o/min. The zeta-potential was measured by electrophoretic measurements (ELS-Z2). Size 
distribution of the Bi2Se3 NPs was determined with the NanoZS Zetasizer particle analyzer 
(Malvern). Sample solutions were prepared by diluting Bi2Se3 NPs into 10 mM PBS solution 
(pH 7.0) and data were acquired in the phase analysis light scattering mode at 25 °C. Stability 
of the Bi2Se3 NPs was also evaluated using light scattering. Bi2Se3 NPs were diluted five times 
in PBS, and size distribution was measured after 3 month in a 5 ml glass cuvette to check the 
possible change in size. 
Biodistribution: The organs and the solutions from the Bi2Se3 NPs-treated mice were 
digested by using a microwave system CEM Mars 5 (CEM, Kamp Lintfort, Germany). The Bi 
and Se content were measured with an ICP-MS, type Agilent 7500 CE (Agilent Technologies, 
Waldbronn, Germany).  
Hematology, biochemistry, and pathology: Using a standard saphenous vein blood 
collection technique, blood was drawn for hematology analysis (potassium EDTA collection 
tube). The analysis of standard hematological and biochemical examination was carried out. 
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For blood analysis, 1 mL of blood was collected from mice and separated by centrifugation 
into cellular and plasma fractions. Mice were sacrificed by isoflurane anesthetic and angio 
catheter exsanguinations, and major organs from those mice were harvested, fixed in 10% 
neutral buffered formalin, processed routinely into paraffin, stained with H&E and pathology 
were examined by a digital microscope. 
In vitro Cytotoxicity Test: Hela cells were cultured at 37 °C in humidified atmosphere 
with 5% CO2 and high-glucose Dulbecco’s modified Eagle's medium (DMEM) which 
contained fetal calf serum (10%), L-glutamine (2.9 mg/ml), streptomycin (1 mg/ml), and 
penicillin (1000 units/ml). The cells (in culture medium) were dispensed in 96-well plates (90 
µl containing 6000 cells per well). Different concentrations of the Bi2Se3 NPs (10 μl) were 
then added to each well. The effect of the concentration of Bi2Se3 NPs was assessed using 
MTT Cell Proliferation and Cytotoxicity Assay Kit. After 24 or 48 hours of treatment, 10 μl 
of MTT reagent was added and incubate for 4 hours, then the medium were replaced with 150 
μl DMSO. The optical absorption in 490 nm signal was recorded with a single tube 
luminometer (TD 20/20, Turner Biosystems Inc., Sunnyvale, CA, USA).  
In Vivo Toxicity: 64 male C57 mice at 11 weeks of age were obtained from the Institute 
of Radiation Medicine (IRM) laboratories and were housed by 2 mice per cage in a 12 h/12 h 
light/dark cycle, and were provided with food and water ad libitum. Mice were randomly 
divided into eight groups (eight mice in each group): 1 day control, 1 day treated, 7 days 
control, 7 days treated, 30 days control, 30 days treated, and 90 days control, 90 days treated 
mice, respectively. A Bi2Se3 NPs solution (200 μL, 2 mg/mL) was used for the animal 
experiment using intraperitoneal injection. The concentration was 20 mg/kg in each mouse. 
The animals were weighed and assessed every day to check the behavioral changes. After 1, 7, 
30, and 90 days treatment, all mice were sacrificed, and blood and organs were collected for 
biochemistry and pathological studies. Mice were sacrificed using isoflurane anesthetic and 
angiocatheter exsanguination with PBS. One mouse from each group was fixed with 10% 
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buffered formalin following phosphate-buffered saline exsanguination. During necropsy, liver, 
kidneys, spleen, heart, lung, testis, brain, bladder, and thymus were collected and weighed. To 
explicitly examine the grade of changes caused by malities, spleen and thymus indexes (  
were used: 
xS )
    
)( animalalexperimentofWeight
)(organ alexperimentofWeight
S
g
mg
x   
 
In vitro DNA Break: A modified version of the alkaline COMET-assay protocol was 
performed to assay the DNA break. In a typical assay, frosted microscope slides were covered 
with 200 μL of 0.1% agarose in PBS. After the solidification of agarose, 2×105 cells 
suspended in 10 μL of PBS and 75 μL of 0.5% low-melting-point agarose were added to each 
slide. After solidification, the slides were placed in cold fresh lyses buffer [2.5 M NaCl, 100 
mM disodium ethylenediaminetetraacetate (EDTA), 10 mM Tris-HCl, and 1% Triton X-100] 
for 1 h and subsequently in a horizontal gel electrophoresis unit (20 × 25 cm) filled with 
chilled electrophoresis buffer (300 mM NaOH and 1 mM Na2EDTA) for 30 min. 
Electrophoresis was then conducted at 14 V for 1 h. The slides were drained, neutralized, and 
dried with ethanol after the electrophoresis. The comets were stained with ethidium bromide. 
The DNA damage was analyzed using Comet Assay Software Project (CASP) software that 
measures the tail moment. 
In vitro Radiation Therapy: Hela cells were incubated in 96-well plates (6000 per well) 
overnight and then exposed to the Bi2Se3 NPs (100 μl, 200 μg/mL) for another 24 h. Then, the 
cells were irradiated under gamma-rays from 137Cs (photon energy 662 keV) with an activity 
of 3600 Ci at the doses of 1, 2, 4, 6, and 8 Gy. After 24 hour of irradiation, cells viability was 
measured by MTT assay.  
In Vivo Radiation Therapy: All animals were purchased, maintained, and handled using 
protocols approved by the Institute of Radiation Medicine (IRM) at the Chinese Academy of 
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Medical Sciences (CAMS). The U14 tumor models were generated by subcutaneous injection 
of 2×106 cells in 50 μL PBS into the right shoulder of female BALB/c mice. The mice were 
treated with the PVP-protected Bi2Se3 NPs when the tumor volume reached 100 to 130 mm3 
(7 days after tumor inoculation). For control, 200 μL saline was injected into mice via 
intraperitoneal injection. For the treatment, 2 mg/mL of the Bi2Se3 NPs was used for the 
animal experiment, and the concentration was raised up to 20 mg/kg in the mice. 
Subsequently, the mice were radiated by 5 Gy gamma rays, and 137Cs with activity of 3600 Ci 
and photon energy of 662 KeV were used. 32 mice were assigned to the following groups 
(eight mice in each group): control, the PVP-protected Bi2Se3 NPs, radiation alone, the Bi2Se3 
NPs plus radiation. The tumor size was measured every two or three days and calculated as: 
volume = (tumor length) × (tumor width)2/2. 
Statistical analysis: All data presented in this study are the average ± SD of at least three 
or more experimental results. The paired Student's t-test was used for the statistical analysis. 
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Figure 1. (a) Representative TEM image of the PVP-protected Bi2Se3 nanoplates (NPs), and 
(b) a magnified image showing a terraced 2-D structure of the NPs. (c,d) High-resolution 
TEM image of the as-prepared PVP-protected Bi2Se3 NPs in (c) horizontal plane and (d) in 
thickness direction. (e) XRD image of the as-prepared PVP-protected Bi2Se3 NPs. The blue 
lines are the peaks of bulk Bi2Se3. 
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Figure 2. In vivo biodistribution and clearance of the PVP-protected Bi2Se3 NPs. (a) Bi 
concentration and (b) Se concentration at the different time points of 1, 7, 30, and 90 days 
after intraperitoneal injection (20 mg/kg). (c,d) Residual amount of Bi (c) and Se (d), and the 
corresponding atomic ratio to the initial atomic amount from the injected Bi2Se3 NPs.  
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Figure 3. Oxidation of the Bi2Se3 NPs in a PBS buffer solution exposed to air for 30 days. (a) 
Digital image of the NPs suspension. The red colored material precipitated on the bottom 
surface of the flask is amorphous Se (indicated with an arrow), (b) TEM image showing 
deformation of the NPs by the oxidation (indicated by an arrow), and (c) XRD spectrum of 
the NPs collected from the PBS buffer solution by vacuum filtration. The red vertical lines 
and the blue vertical lines at the bottom  present  XRD peaks of pure Bi2Se3 and Bi2O2.33. 
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Figure 4. Oxidation process of Bi2Se3 NPs. (a) Time-dependent atomic ratio of Bi to Se in 
vitro. (b) Time-dependent concentration of Bi which was measured by ICP-MS in vivo. (c) 
Illustration to describe the dissolution and oxidation of the Bi2Se3 NPs after intraperitoneal 
injection. 
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Figure 5. (a) Hematology data of the mice treated with the PVP-protected Bi2Se3 NPs. The 
data were collected at the different time points of 1, 7, 30, and 90 days after intraperitoneal 
injection (20 mg/kg). The terms are following: red blood cells (RBC), white blood cells 
(WBC), platelets (PLT), mean corpuscular hemoglobin (MCH), mean corpuscular 
hemoglobin concentration (MCHC), mean corpuscular volume (MCV), hemoglobin (HGB), 
and hematocrit (HCT). The terms ‘Con.’ and ‘Bi2Se3’ in the figures indicate controlled mice 
without the Bi2Se3 NPs and the mice treated with the NPs, respectively. (b) Blood 
biochemistry analysis of the mice treated with the PVP-protected Bi2Se3 NPs at the different 
time points of 1, 7, 30, and 90 days. The results show mean and standard deviation of 
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aminotransferase (ALT), aminotransferase (AST), total protein (TP), albumin (ALB), blood 
urea nitrogen (BUN), creatinine (CREA), globulin (GOLB), and total bilirubin (TBIL). Data 
were obtained by Student’s t-test.  
 
Figure 6. Pathological data from the liver, spleen, and kidney of the mice treated with the 
PVP-protected Bi2Se3 NPs. The data were collected at different time points of 1, 7, 30, and 90 
days after injecting 20 mg/kg dose.  
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Figure 7. (a) Viability of Hela cells after incubation with the PVP-protected Bi2Se3 NPs for 
24 and 48 h. (b) Viability of Hela cells treated with only radiation [control, black line], the 
Bi2Se3 NPs (100 μg/mL) + radiation  [red line], and the Bi2Se3 NPs (200 μg/mL) + radiation 
[blue line]. (c) Tail moment of Hela cells treated with the Bi2Se3 NPs, radiation (3 Gy), and 
the Bi2Se3 NPs + radiation (3 Gy). (d) Representative cell images of fluorescent DNA stain of 
control, radiation group, the Bi2Se3 NPs, and the Bi2Se3 NPs + radiation (3 Gy). 
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Figure 8. In vivo biodistribution and passive targeting of the PVP-protected Bi2Se3 NPs. 
Concentration of Bi and Se in blood (a) and in tumor (b) at the different time points of 0.5, 1, 
2, 6, 12, 24, 72 h after intraperitoneal injection (20 mg/kg). Time-course studies of the tumor 
volume (c) and the tumor weight (d) of mice treated with the PVP-protected Bi2Se3 NPs at the 
concentration of 20 mg/kg. Data was obtained by Student’s t-test.  
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Figure 9. Three dimension in vivo X-ray CT imaging of tumor tissue (red circle) and bladder 
(red circle) from the PVP-protected Bi2Se3 NPs from front view (a) and from side view (b) at 
24 h. (c-e) Two dimension images of the tumor tissue (red arrow) were taken at (c) 3 h, (d) 6 
h. and (e) 24 h. (f-h) Two dimension images of bladder (red arrow) from PVP-protected 
Bi2Se3 NPs treated mice at (f) 3 h, (g) 6 h, and (h) 24 h. 
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Figure S1. Size distribution of the as-prepared PVP-protected Bi2Se3 NPs obtained from 
TEM images (a), and from dynamic light scattering spectra in PBS buffer solution (b). Data in 
(b) contain the initial size and the value after 1 month. 
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Figure S2. (a)The body weight, (b) thymus index, and (c) spleenindex of the mice treated 
with the PVP-protected Bi2Se3 NPs. 
 
 
 
 
Figure S3. Pathologicalimage of the heart, lung,and testis of the control mice group 
(untreated) and of the mice treated with the PVP-protected Bi2Se3 NPs. 
 
 
